40505-27-9

Usage

Uses

Used in Pharmaceutical Industry:
4'-Demethylpodophyllotoxin is used as a pharmaceutical compound for its potential therapeutic properties. The demethylation at the 4' position may alter the compound's interaction with biological targets, possibly enhancing its efficacy or reducing side effects compared to the parent compound, podophyllotoxin.
Used in Anticancer Applications:
In the field of oncology, 4'-Demethylpodophyllotoxin may be employed as an anticancer agent. The structural modification could potentially improve the compound's ability to target and inhibit specific cancer-related pathways, leading to the suppression of tumor growth and progression.
Used in Drug Delivery Systems:
4'-Demethylpodophyllotoxin can also be utilized in the development of novel drug delivery systems. The structural change at the 4' position might enhance the compound's solubility, stability, or bioavailability, allowing for more effective delivery to target cells and improved therapeutic outcomes.
Used in Chemical Research:
In the realm of chemical research, 4'-Demethylpodophyllotoxin serves as a valuable compound for studying the effects of structural modifications on the biological activities of heterocyclic compounds. This knowledge can be applied to the design and synthesis of new molecules with improved properties and applications in various industries, including pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 518-28-5 podofilox 
• 6559-91-7 4'-demethylepipodophyllotoxin 
• 477-47-4 (+/-)-podophyllotoxin 

Downstream Products

• 518-28-5 podofilox 
• 22823-30-9 (5aS)-9c-acetoxy-5c-(4-acetoxy-3,5-dimethoxy-phenyl)-(5ar,8ac)-5,8,8a,9-tetrahydro-5aH-furo[3',4';6,7]naphtho[2,3-d][1,3]dioxol-6-one 
• 22823-30-9 (5aR)-9t-acetoxy-5t-(4-acetoxy-3,5-dimethoxy-phenyl)-(5ar,8at)-5,8,8a,9-tetrahydro-5aH-furo[3',4';6,7]naphtho[2,3-d][1,3]dioxol-6-one 
• 477-47-4 picropodophyllotoxin 
• 112066-16-7 4'-O-demethylpicropodophyllotoxin 
• 23412-22-8 4'-benzyloxycarbonyl-4'-demethylpodophyllotoxin 
• 16477-16-0 4'-O-demethyl-4β-bromo-4-desoxypodophyllotoxin 
• 3590-93-0 4'-demethyl-4-deoxypodophyllotoxin 
• 1180-34-3 podophyllotoxinyl acetate 
• 1174-97-6 6,7-O,O-demethylenepodophyllotoxin 
• 50905-41-4 3',4'-demethyl-3',4'-dioxopodophyllotoxin 
• 7470-99-7 2-(3,4,5-Trimethoxybenzoyl)-4,5-(methylenedioxy)benzoic Acid 
• 156350-44-6 Carbonic acid benzyl ester 4-((5R,5aR,8aR)-6,9-dioxo-5,5a,6,8,8a,9-hexahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)-2,6-dimethoxy-phenyl ester 
• 93780-84-8 4'-demethylpodophyllotoxone 

Relevant academic research and scientific papers

HUMAN TOPOISOMERASE II-TARGETING ORGANOPLATINUM COMPOUNDS

Some organoplatinum compounds have been synthesized. These organoplatinum compounds are designed to be human Topoisomerase II-targeting drugs.

ORGANOPLATINUM COMPOUNDS AND PHARMACEUTICAL COMPOSITION THEREOF AND METHOD OF PREPARING CRYSTAL OF hTop2

Some organoplatinum compounds have been synthesized. These organoplatinum compounds are designed to be human Topoisomerase II-targeting drugs.

Comparative study of microtubule inhibitors - Estramustine and natural podophyllotoxin conjugated PAMAM dendrimer on glioma cell proliferation

The synthetic estramustine (EM) and natural podophyllotoxin (PODO) anti-mitotic agents that inhibit tubulin polymerization are known anticancer agents. As low bioavailability limits their anticancer properties, we investigated whether conjugation with PAMAM dendrimer (D) could enhance the activity of D-EM and D-PODO by altering their release pattern. Release kinetics indicated synthesized conjugates to be stable against hydrolytic cleavage and showed sustained release characteristics. However, release of D-EM was slow compared to D-PODO conjugate. Antitumor effect of these conjugates on glioma cells revealed (i) increased cell death and cell cycle arrest (ii) decreased migration and (iii) increased tubulin depolymerization as compared to free drug. Importantly, the effects of natural PODO conjugate on glioma cell survival and migration is more pronounced than D-EM.

Etoposide analogues

Compounds that are analogs of etoposide and exhibit antitumor activity are disclosed. The compounds of the present invention have the following formula: STR1 where: R1 is β-OCH2 CH2 NH2 β-NHCH(CH3)CH2 OH, β-NHCH2 CH(CH3)OH, β-Cl, β-Br, β-OH, α-OH, β-NH, α-NH2, β-NHCH2 CH2 OH, α-NHCH2 CH2 OH, β-NHCH2 CH2 CH3, β-NHCH2 CH2 OCH3, β-NHCH2 CH=CH2, β-NHCH2 CH(OH)CH3, β-NHCH2 CH2 CH2 OH, β-OCH2 CH2 OH, STR2 R2 is H, or Br; R1 is H, or Br; R4 is H, or Br; R5 is H, or Br; and R6 is H, or --CH3.

Syntheses of All Four Possible Diastereomers of Etoposide and Its Aminoglycosidic Analogues via Optical Resolution of (+/-)-Podophyllotoxin by Glycosidation with D- and L-Sugars

Syntheses of all four possible diastereomers of etoposide and its aminoglycosidic analogues have been achieved via optical resolution of (+/-)-podophyllotoxin by glycosidation with D- and L-sugars.